Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Giredestrant becomes First Oral SERD to show IDFS benefit in adjuvant EBC trial.
This is welcome news
Looking forward to details.
But as per published methodology, there is no USE of adjuvant cdk4/6 inhibitors in control arm .
If that’s not there , then how will this change current standard of care ?
It will not?
The other two oral SERDs Camizestrant ( Cambria 2 ) and Elacestrant ( Elegance trial ) both have better control arms .
Both of these trials have incorporated CDK inhibitors in control arm.”
More posts featuring Amol Akhade.
